NCT06344052 2024-09-20
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Stamford Pharmaceuticals, Inc.
Phase 2 Recruiting
Clinical Trials
13 trialsNCT02667574 2022-10-17
VISMONEO
University Hospital, Lille
Phase 2 Completed
NCT03035188 2022-02-11
NICCI
SRH Wald-Klinikum Gera GmbH
Phase 2 Completed
NCT01556009 2020-11-02
Vismodegib
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT02956889 2020-01-29
virgilio
Istituto Clinico Humanitas
Phase 2 Terminated
NCT02067104 2019-08-14
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
University of Arizona
Phase 2 Terminated
NCT01700049 2019-05-23
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Mayo Clinic
Phase 2 Completed
NCT01815840 2017-09-28
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Hoffmann-La Roche
Phase 2 Completed
NCT01898598 2017-05-08
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Terminated
NCT00833417 2015-05-20
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT01543581 2014-09-26
Erivedge
Loma Linda University
Phase 2 Completed
NCT01201915 2014-06-24
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed